About Annexon Biosciences
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.
|
|
|
51-200 employees
View all Annexon Biosciences employees
|
|
Biotechnology Research
|
|
650-822-5500
|
|
180 Kimball Way, Suite 200, South San Francisco, California 94080, US
|
|
2011
|
|
Ophthalmology, Autoimmune, Neurodegeneration
|
Annexon Biosciences Alternatives
Frequently Asked Questions about Annexon Biosciences
Doug Love is the CEO of Annexon Biosciences. To contact Doug Love email at [email protected] or [email protected].
The decision makers in Annexon Biosciences are Aj Acker, Akbar Khan, Donald Fong, etc. Click to Find Annexon Biosciences decision makers emails.
Annexon Biosciences Staff Directory
Search Annexon Biosciences Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
